In re Effexor XR Antitrust Litigation

In the wake of the Supreme Court’s landmark decision in FTC v. Actavis, Goodwin attorneys have been at the forefront of litigating antitrust challenges to settlement agreements between brand and generic pharmaceutical companies. In this case, Goodwin filed an amicus brief on behalf of the Association for Accessible Medicines (formerly known as the Generic Pharmaceutical Association) addressing the meaning of the “large, reverse payment” test laid out by the Supreme Court in Actavis.

In re Effexor XR Antitrust Litigation

 

Download PDF

Leave a reply

Your email address will not be published. Required fields are marked *